Outcomes of topical Ringers Lactate solution as treatment for Phase – 1 Retinopathy of Prematurity

Four preterm neonates were enrolled in the study. Among the four neonates, one developed Staged ROP (Phase 2) approximately two weeks earlier in the untreated eye compared to the treated eye. Two neonates showed simultaneous progression to staged ROP in both eyes, and one neonate was lost to follow-up. No local or systemic adverse effects were observed during the study period. This pilot study demonstrates a favorable local and systemic safety profile of topical Ringer’s lactate. However, further studies, including dose-escalation trials with larger sample sizes, are required to evaluate its efficacy in preventing progression from Phase 1 to Phase 2 ROP.